He succeeds Mr. Axel Leimer, AMSilk’s former CEO, who had successfully run the company for six years until February 28, 2014. As CEO Mr. Klein is responsible for the strategic positioning and the future growth of the company.
Most recently Mr. Klein worked for Evonik Industries AG. In 2011 Evonik acquired nanoresins AG and Hanse Chemie AG. Mr. Klein was a member of the executive committee of both companies since 2006. In these functions he had a significant impact on the growth of both companies, the integration of new technologies, the optimization of manufacturing processes as well as the international expansion.
Previously, he was a member of the executive board of Mulligan BioCapital AG, Hamburg and Munich. Mulligan used to be a long-term investor in medical technology, biotechnology and high technology enterprises in the US and Europe. Among other responsibilities Mr. Klein shared responsibilty for the initial public offerings of two portfolio companies as well as several trade sales to strategic investors. Prior to joining Mulligan he was the commercial head and managing director of subsidiaries of Fresenius AG, Bad Homburg.
With regard to his new tasks at AMSilk GmbH Mr. Klein stated, „AMSilk has the unique potential to market spider silk protein across various application areas. The key goal is to position the product successfully in high revenue markets and to generate additional collaborations and licensing deals.“.
Mr. Helmut Jeggle, managing director of AT Newtec GmbH and representative of AMSilk’s largest shareholder commented, „Our thanks go to Mr. Leimer for his magnificent performance ever since the founding of AMSilk in 2008 and for his outstanding personal commitment that allowed him to take AMSilk to where it is today. We also wish Mr. Klein our best for the challenges ahead.“
Dr. Matthias Kromayer, chairman of the board of AMSilk GmbH and member of the executive committee of MIG Verwaltungs AG mentioned, „We feel enthusiastic that we managed to hire Jens Klein who happens to be not only an expert with comprehensive industry knowledge but also a man who can skillfully formulate ambitious goals and then turn them into reality. Beyond this he combines extensive experience in strategically positioning companies, building sales organizations, managing corporate finances and working with the financial markets with his broad skills and know- how in high technology markets.
AMSilk is a privately-held company that develops, manufactures and markets novel cosmetics, medical technology and drug delivery products as well as technical fibers on a worldwide basis.
Spider silk has attracted man’s interest for thousands of years, mainly due to its toughness and elasticity. The silk is biocompatible and can be used in formulations for specialized coatings, films, nonwovens and in pharmaceuticals. Spider silk has evolved over millions of years resulting in a combination of properties that far exceed any man-made material. AMSilk has developed a proprietary process for producing spider silk on an industrial scale.
AMSilk was founded in 2008 as a spin-off of Technische Universität Munich and is located at the IZB in Planegg near Munich. AMSilk’s investors are Munich-based MIG Funds and AT Newtec GmbH (a company of the Strüngmann family office). Projects are partially funded by grants from the German Federal Ministry of Education and Research as well as the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology with project management provided by the PTJ and VDI. AMSilk is a registered trademark of AMSilk GmbH, Germany. For further information visit: www.amsilk.com
Am Klopferspitz 19 im IZB 82152 Planegg; Germany
Phone: +49 (0)89 38156-4430
Email: [email protected]